美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

Astellas Pharma, Inc.

15.09

-0.3400-2.20%

成交量：4,085.00

成交额：6.16万

市值：270.16亿

市盈率：202.95

高：15.31

开：15.00

低：14.93

收：15.43

52周最高：17.35

52周最低：8.97

股本：17.90亿

流通股本：17.45亿

量比：0.28

换手率：0.00%

股息：0.51

股息率：3.40%

每股收益(TTM):0.0744

每股收益(LYR):0.0628

净资产收益率：19.82%

总资产收益率：7.38%

市净率：2.44

市盈率(LYR):240.13

数据加载中...

总览公司新闻资讯公告

概念

no data

没有相关数据

资金流向

资金流入：

资金流出：

新闻资讯

安斯泰来制药：FDA根据《处方药使用者费用法案》设定2026年8月17日为关键审批日期

安斯泰来：EV-304研究中围术期enfortumab vedotin联合帕博利珠单抗的安全性特征与既往联合用药经验一致

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/ALPMY"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ALPMY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","market":"US","secType":"STK","nameCN":"Astellas Pharma, Inc.","latestPrice":15.09,"timestamp":1777298700000,"preClose":15.43,"halted":0,"volume":4085,"delay":15,"changeRate":-0.02203499675955929,"floatShares":1745183156,"shares":1790310070,"eps":0.074352,"marketStatus":"交易中","change":-0.34,"latestTime":"04-27 10:05:00 EDT 延时","open":15,"high":15.31,"low":14.9316,"amount":61560.521075000004,"amplitude":0.024524,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":0.074352,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1777320000000},"marketStatusCode":2,"adr":0,"adrRate":1,"exchange":"PINK LIMITED","adjPreClose":15.43,"volumeRatio":0.275752},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ALPMY\",,,,,undefined,":{"symbol":"ALPMY","floatShares":1745183156,"roa":"7.38%","roe":"19.82%","lyrEps":0.062841,"volumeRatio":0.275752,"shares":1790310070,"dividePrice":0.5124,"high":15.31,"amplitude":0.024524,"preClose":15.43,"low":14.9316,"week52Low":8.97,"pbRate":"2.44","psRate":"2.09","week52High":17.35,"institutionHeld":0,"latestPrice":15.09,"eps":0.074352,"divideRate":0.033956,"volume":4085,"delay":15,"ttmEps":0.074352,"open":15,"prevYearClose":13.29,"prevWeekClose":15.43,"prevMonthClose":16.22,"prevQuarterClose":16.22,"fiveDayClose":16.18,"twentyDayClose":16.09,"sixtyDayClose":13.91},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ALPMY\",params:#limit:5,,,undefined,":[{"date":"2026-04-27","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1777276800000,"name":null,"time":"","dateTimestamp":1777262400000,"actualEps":null},{"market":"US","date":"2025-02-04","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1738645200000,"reportTimeType":"","actualEps":null},{"date":"2024-08-01","symbol":"ALPMY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722499200000,"name":null,"time":"","dateTimestamp":1722484800000,"actualEps":null},{"market":"US","date":"2024-04-25","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1714017600000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2024-02-05","symbol":"ALPMY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1707109200000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ALPMY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ALPMY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1758254400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ALPMY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1159770601","title":"安斯泰来制药：FDA根据《处方药使用者费用法案》设定2026年8月17日为关键审批日期","url":"https://stock-news.laohu8.com/highlight/detail?id=1159770601","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1159770601?lang=zh_cn&edition=fundamental","pubTime":"2026-04-20 18:48","pubTimestamp":1776682090,"startTime":"0","endTime":"0","summary":"根据《处方药使用者费用法案》框架，美国食品药品监督管理局已为安斯泰来制药的核心新药申请划定重要时间节点——2026年8月17日被正式确立为监管审评的目标行动日期。这一关键时间点的设定，标志着该创新疗法的审评进程进入倒计时阶段，为市场预期提供了明确的时间坐标。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0234572021.USD","LU0306807586.USD","ALPMF","LU0306806265.USD","LU1057294990.SGD","ALPMY","LU1894683348.USD","LU0985481810.HKD","SGXZ57979304.SGD","LU1066051498.USD","LU0868494617.USD","LU0321505868.SGD","SG9999001176.USD","LU1894683264.USD","BK4533","IE00B19Z3B42.SGD","SG9999001176.SGD","SG9999011175.SGD","BK4534","SG9999013999.USD","IE00BLSP4239.USD","BK4585","IE00BLSP4452.SGD","LU0289739699.SGD","LU0456855351.SGD","BK4568","LU0225284248.USD","BK4550","LU0122379950.USD","BK4588","LU1023059063.AUD","BK4007","SG9999003800.SGD","IE00B19Z3581.USD","IE000M9KFDE8.USD","SG9999002224.SGD","LU0058720904.USD","SG9999002232.USD","IE00BBT3K403.USD","IE0002270589.USD","LU0321505439.SGD","LU1883839398.USD","BK4581","LU0170899867.USD","LU1066053197.SGD","BK4592","BK4599"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164144381","title":"安斯泰来：EV-304研究中围术期enfortumab vedotin联合帕博利珠单抗的安全性特征与既往联合用药经验一致","url":"https://stock-news.laohu8.com/highlight/detail?id=1164144381","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164144381?lang=zh_cn&edition=fundamental","pubTime":"2026-02-27 23:05","pubTimestamp":1772204701,"startTime":"0","endTime":"0","summary":"根据EV-304研究数据，安斯泰来制药公司公布的最新结果显示，在围术期使用enfortumab vedotin联合帕博利珠单抗的治疗方案，其安全性特征与先前对该联合疗法的经验保持一致。\n这一发现进一步支持了该联合治疗方案在临床应用中的安全性一致性，为后续治疗策略的制定提供了重要参考依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0321505439.SGD","LU1066051498.USD","SG9999003800.SGD","SG9999001176.SGD","LU0868494617.USD","BK4007","SG9999001176.USD","LU0225284248.USD","LU0234572021.USD","BK4592","BK4534","LU0170899867.USD","LU0306807586.USD","IE0002270589.USD","LU1894683264.USD","SG9999011175.SGD","LU1883839398.USD","IE00B19Z3B42.SGD","LU1066053197.SGD","BK4568","LU0289739699.SGD","LU1894683348.USD","IE00BLSP4452.SGD","SG9999002224.SGD","SG9999002232.USD","SGXZ57979304.SGD","LU0985481810.HKD","IE000M9KFDE8.USD","LU0321505868.SGD","LU0122379950.USD","LU0456855351.SGD","BK4581","LU0225771236.USD","BK4588","LU1023059063.AUD","ALPMY","BK4585","IE00BLSP4239.USD","LU0058720904.USD","BK4533","LU1057294990.SGD","IE00B19Z3581.USD","IE00BBT3K403.USD","BK4599","SG9999013999.USD","LU0306806265.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ALPMY\",params:#limit:6,delay:false,,,undefined,":[]}}